Abstract:Glypican-3 (GPC3) is highly expressed in many of hepatocellular carcinoma, hepatoblastoma, ovarian clear cell carcinoma, and squamous cell lung carcinoma, but not expressed in almost all normal tissues, making it an excellent target for cancer immunotherapy. We identified each HLA-A24 and -A2-restricted GPC3-derived peptide and had conducted various clinical trials administering these peptides. All five cases of refractory hepatoblastoma, who had repeated relapses and remissions, are surviving for more than 9 years without recurrence by the only administering these peptide vaccines. We established many kinds of peptide-specific CTL clones with high avidity from PBMC of one of the female HLA-A*02:01-positive refractory hepatoblastoma patient treated with GPC3-derived peptide. Through collaborating research with Takara Bio Inc., which has siTCR technology and extensive experience in developing TCR-T cell therapies including NY-ESO-1 TCR-T, we identified most effective two kinds of TCR by creating a viral vector, preparing TCR-expressing T cells, and evaluating them in various in vitro/in vivo experiments. These TCR-gene engineered T cell can kill cancer cells presenting glypican-3-derived peptides, so this TCR-T therapy has proven to be a promising treatment for patients with cancers that are HLA-A2 positive and express GPC3. The development of TCR-T has been overshadowed by the overwhelming increase in the number of CAR-Ts developed in recent years, but while CAR-Ts have struggled in solid cancers, there have been some reports of successful cases in TCR-Ts and remains a promising treatment. Although GPC3 is a membrane protein, it is not necessarily expressed on the cell membrane and is often expressed within the cell, so we believe that TCR-T is more effective than CAR-T, which targets GPC3. TCR-T cell therapy targeting GPC3 has not yet been implemented anywhere in the world, and we hope this TCR-T therapy as an effective treatment for hepatocellular carcinoma, an intractable cancer with a 10-year survival rate of only 15%, refractory childhood hepatoblastoma, ovarian clear cell carcinoma and lung squamous cell carcinoma that are difficult to respond to anticancer drugs. This development was based on an unmet medical need, and HLA-A2 is found not only in 40% of Japanese, but also in many Caucasians, making it versatile and possible for international expansion. Citation Format: Tsuyoshi Terada, Kazunobu Ohnuki, Manami Shimomura, Toshihiro Suzuki, Yasunori Amaishi, Kaho Takeichi, Sachiko Okamoto, Norihiro Fujinami, Kazumasa Takenouchi, Nobuo Tsukamoto, Kayoko Shoda, Toshiaki Yoshikawa, Tetsuya Nakatsura. T cell receptor-engineered T cell therapy using TCR gene derived from an HLA-A2 hepatoblastoma patient who was completely cured by administration of glypican-3 peptide vaccine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3614.

T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease

Genetically engineered T cells for cancer immunotherapy

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy

Engineered Regulatory T Cells Prevent Graft-Versus-host Disease While Sparing the Graft-Versus-leukemia Effect after Bone Marrow Transplantation.

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function

Gene editing of gene to redirect regulatory T cells for adoptive T cell transfer

Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma

Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers

Antigen‐specific TCR‐T cells from Rag2 gene‐deleted pluripotent stem cells impede solid tumour growth in a mouse model

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Engineered off-the-shelf therapeutic T cells resist host immune rejection

Abstract 3614: T cell receptor-engineered T cell therapy using TCR gene derived from an HLA-A2 hepatoblastoma patient who was completely cured by administration of glypican-3 peptide vaccine

Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors

Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures